Stock·NASDAQ·Healthcare
Gilead Sciences Inc (GILD)
- Market cap
- $197.25B
- Dividend yield
- 2.04%
- Street target
- $165.00median of 28 analysts
- 52-week range
- $114.02 $160.51
GILD stock forecast today
Where GILD stands today, and what CleaRank Financial AI makes of it.
GILD at a glance
Gilead Sciences Inc (GILD): Buy, 65/100 on CleaRank's AI score.
- Trend Up: the price is above both its 50- and 200-day moving averages ($149.65 and $139.25).
- Earnings GILD beat estimates in 8 of its last 8 quarters, yet fell the next day after 3 of those beats.
- Insiders Insiders sold $98.6M and made no open-market purchases over the last 18 months.
Figures as of October 27, 2026.
CleaRank Financial AI
GILD carries a CleaRank rating of Buy and a model score of 65/100.
Trend is the biggest contributor, with the price 14.24% above its 200-day average and 6.30% above its 50-day average, and the 50-day average 7.47% above the 200-day. Valuation is the largest drag: no meaningful P/E because of the losses, and a P/S of 6.48 that is 90.6% above the sector median. The 50-day average is $149.65 and the 200-day is $139.25, and over the past year the price rose 32.05%.
Only on CleaRank
Figures we compute ourselves from GILD's own price, earnings and insider-filing history. Tap one to see it in context.
GILD stock price and trading
The chart, today's range and how far the price has moved over each period.
Trend checks
4/4Price above its 50-day average ›
The price of $159.08 is 6.3% above the 50-day simple moving average of $149.65.Price above its 200-day average ›
The price is 14.2% above the 200-day simple moving average of $139.25.50-day average above the 200-day ›
The 50-day average ($149.65) is 7.5% above the 200-day average ($139.25), the arrangement of a rising longer-term trend.In the upper half of its 52-week range ›
The price sits at 97% of its 52-week range, between $114.02 and $160.51.
GILD share price
Pick a period: each tab shows how far GILD has moved over it, to the last close.
Today's trading
Where GILD sits inside today's range and its 52-week range.
GILD fundamentals and valuation
Valuation against the sector, and the revenue and earnings behind it.
Valuation and quality checks
2/4P/S below the sector median ›
The price-to-sales ratio of 6.48 is 90.5% above the sector median of 3.4.Profitable over the last 12 months ›
Net income over the last 12 months was -$3.2B on revenue of $30.5B, a net margin of -10.6%.Beat estimates in most recent reports ›
GILD beat the EPS estimate in 8 of its last 8 reports.Pays a dividend ›
The trailing dividend yield is 2.04%, or $3.25 a share a year.
Key statistics
The headline figures for GILD.
As of October 27, 2026, GILD trades at $159.08, with a market value of $197.25B, no P/E ratio (its trailing earnings are negative) and a dividend yield of 2.04%.
What the numbers say
CleaRank Financial AI's reading of GILD's valuation, growth and risks.
GILD cannot be valued on a P/E, because that figure is not meaningful: its earnings per share over the last 12 months are negative. On sales, the price-to-sales ratio of 6.48 is 90.6% above the sector median of 3.4.
GILD is losing money. Its net margin stands at -10.64% and its operating margin at 33.68%, while return on equity of -20.68% sits below the sector median of 7.3%. On growth, the company is ahead of its sector: revenue rose 10.20% in the latest quarter year on year, compared with a sector median of 8.1%. Debt-to-equity is 2.23, and the trailing dividend yield of 2.04% pays $3.25 a share each year.
The record is a clean sweep: 8 beats in 8 reports, but beats have not guaranteed gains: the stock fell the next day after 3 of them. The February 10, 2026 report stands out among the few before the latest: a beat of 2.76%, after which the stock rose 5.82%.
Daily swings are the main thing to plan around: on an average session GILD has moved 1.58%, and its beta against the S&P 500 is 0.33. Over the last 18 months insiders sold $98.6M of stock and bought none on the open market. Those sales are often planned in advance or made to cover tax on vesting shares, so they carry less weight than purchases would.
GILD against the Healthcare sector
How GILD compares with the median Healthcare stock CleaRank tracks.
Price to sales vs sector: On price-to-sales, the yardstick used here in place of P/E, GILD trades at 6.48x, +90% versus the sector average of 3.40x.
Return vs XLV: Since May 15, 2025, GILD has gained 58.5% against a gain of 37.3% for XLV.
Performance against XLV
GILD and the Healthcare sector fund over the same days.
Revenue and earnings
How much GILD sells, and how much of it becomes profit.
Revenue growth: Revenue grew 2.4% in FY2025 to $29.4B, from $28.8B a year earlier.
Profit margin: The net margin was 28.9% in FY2025, up from 1.7% the year before.
Profitable: GILD earned $8.5B in FY2025.
Earnings reality check
Did GILD beat what analysts expected, and how did the stock react?
Earnings record: GILD beat the analyst estimate in 8 of the last 8 quarters.
Market reaction: The stock fell in the first session after 3 of those 8 beats, so a beat has not been enough on its own.
| Report | Estimate | Actual | Surprise | First session | 5 sessions |
|---|---|---|---|---|---|
| Aug 4, 2026after close | -$7.25 | -$6.75 | +6.90% | -2.58% | +0.38% |
| May 7, 2026after close | $1.91 | $2.03 | +6.28% | -2.04% | -1.49% |
| Feb 10, 2026after close | $1.81 | $1.86 | +2.76% | +5.82% | +3.74% |
| Oct 30, 2025after close | $2.14 | $2.47 | +15.42% | +1.14% | +4.19% |
| Aug 7, 2025after close | $1.96 | $2.01 | +2.55% | +8.28% | +7.93% |
| Apr 24, 2025after close | $1.78 | $1.81 | +1.69% | -2.81% | -2.73% |
| Feb 11, 2025after close | $1.70 | $1.90 | +11.76% | +7.46% | +11.97% |
| Nov 6, 2024after close | $1.55 | $2.02 | +30.32% | +6.77% | +1.03% |
As of October 27, 2026, GILD has beaten the analyst EPS estimate in 8 of its last 8 reported quarters and fell in the first trading session after 3 of those beats; its latest report, on August 4, 2026, came in 6.90% above the estimate and the stock moved -2.58% in the first session.
The first session is the first full trading day on the news: the report day itself for a report before the open, the next day for one after the close. Surprise is actual EPS against the consensus estimate.
GILD AI analysis and technical indicators
CleaRank's score and reasoning, the indicators behind it, and what the price moves with.
Momentum checks
3/3RSI not overbought or oversold ›
The 14-day RSI is 62.4, showing bullish momentum without being overbought.RSI above 50 ›
An RSI of 62.4 is above the 50 midpoint, so buyers have had the upper hand over the last 14 days.MACD line above zero ›
The MACD line is positive, so the 12-day average is above the 26-day average.
CleaRank Financial AI analysis of GILD
The score, the reasoning behind it, and what could move the price next.
Gilead Sciences Inc (GILD) is in an uptrend. At $159.08, the price is 14.24% above its 200-day average of $139.25 and 6.30% above its 50-day average of $149.65. Near the top of its 52-week range, the price is 0.89% below the high of $160.51 and 39.52% above the low of $114.02. The 50-day average is 7.47% above the 200-day, so the two averages are also arranged in an uptrend's order.
The 14-day RSI of 62.4 is in the bullish zone, below the overbought line, and the MACD line is positive. The recent returns are all positive: the price rose 18.43% over the past three months, rose 23.07% over the past six months and rose 32.05% over the past year.
Rating reaffirmed ›
B of A Securities kept its Buy rating on October 20, 2026.
Source: Analyst action, B of A Securities, October 20, 2026
Earnings beat, but the stock fell ›
The August 4, 2026 report beat the EPS estimate by 6.90%, and the share price fell 2.58% in the first session after it.
Source: Earnings report, August 4, 2026
- Keep an eye on the two nearest levels: the 52-week high at $160.51 sits above the price, and the 20-day EMA at $153.40 sits below it.
- The 14-day RSI reads 62.4, in the bullish zone, with the MACD line positive; readings above 70 or below 30 mark stretched momentum.
- After the August 4, 2026 report the share price fell 2.58% in the first session; GILD beat estimates in 8 of the last 8 reports.
GILD's uptrend depends on the price holding above its 50-day average of $149.65 and its 200-day average of $139.25. A close below the 50-day average would be the first sign of that trend weakening. If the price pulls back, the first level it would reach is the 20-day EMA at $153.40.
The next level overhead is the 52-week high at $160.51. The RSI sits in the bullish zone, which means momentum still supports the move.
Technical indicators
Momentum and trend for GILD, from its daily closes.
As of October 27, 2026, with GILD at $159.08, its 14-day RSI is 62.4 (showing bullish momentum without being overbought), its 50-day simple moving average is $149.65 and its 200-day is $139.25.
Calculated by CleaRank on daily closes as of October 27, 2026: Wilder's 14-day RSI, 50- and 200-day simple moving averages, MACD line (12, 26). How we calculate these
What GILD moves with
Correlation of daily returns over one year: +1 moves in step, 0 has no link, -1 moves the opposite way.
As of October 27, 2026, GILD's 1-year correlation of daily returns is +0.22 with S&P 500 (SPY), +0.13 with Nasdaq 100 (QQQ), +0.03 with Bitcoin (BTC) and +0.04 with gold (XAU).
GILD price target and analyst forecast
The analysts' target range and how their ratings split.
Analysts checks
3/3Most analysts rate it a buy ›
22 of 28 analysts rate it a buy or strong buy, 5 a hold and 1 a sell.Median target above the price ›
The median 12-month target of $165.00 is 3.7% above the price.More buy ratings than three months ago ›
22 of 28 rate it a buy now, against 22 of 29 three months ago.
GILD Wall Street View
12-month price targets
Ratings
Recent rating actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Oct 20, 2026 | B of A Securities | Maintains | Buy |
| Oct 8, 2026 | RBC Capital | Maintains | Sector Perform |
| Oct 8, 2026 | Cantor Fitzgerald | Reiterates | Overweight |
| Oct 7, 2026 | Truist Securities | Maintains | Buy |
| Oct 7, 2026 | JP Morgan | Maintains | Overweight |
| Oct 7, 2026 | Morgan Stanley | Maintains | Overweight |
As of October 27, 2026, 28 Wall Street analysts cover GILD: 22 rate it a buy or strong buy, 5 a hold and 1 a sell or strong sell. Their 12-month price targets range from $126.00 to $185.00. The median GILD price target is $165.00, 3.7% above the price of $159.08.
Source: TwelveData analyst consensus. Targets and ratings belong to the analysts, not to CleaRank.
GILD trade plan: entry, stop loss and targets
Entry, stop and target levels from the moving averages and recent volatility. Educational, not advice.
GILD trade plan
Entry, stop and target levels, sized to your account. Change the bias or the risk and every level updates.
Long entry pick an entry style
Risk management
Profit targets (Based on Conservative Entry)
These levels come from GILD's moving averages and recent volatility, not from a forecast. Educational levels, not financial advice; the full disclaimer is at the foot of the page.
Risk profile
How much GILD tends to move, against the market and on its own.
GILD price history and drawdowns
GILD's worst falls and recoveries, what $10,000 became, and which months have been kind to it.
Track record checks
3/4Average daily move under 2% ›
The price has moved 1.58% on an average day (30-day standard deviation of daily returns).Recovered from its worst fall ›
The worst fall was 29.6%, from April 2020 to December 2020, regained by October 2022.Most 1-year holds ended higher ›
65% of 1-year holding periods in the last 10 years ended with a gain.Beat the S&P 500 since the chart begins ›
$10,000 invested in October 2016 is now worth $30,565, against $42,376 in the S&P 500 (SPY).
GILD Drawdowns & Recovery
As of October 27, 2026, GILD's worst peak-to-trough fall over the last 10 years with dividends reinvested was -29.6% (April 2020 to December 2020); it regained that peak by October 2022, 22 months after the low, and 65% of 1-year holding periods ended with a gain.
From weekly closing values with dividends reinvested. A drawdown is the fall from the highest value reached so far to a later low.
Growth of $10,000
What $10,000 put into GILD in October 2016 is worth now, against the same amount in the S&P 500.
Against the market: GILD trailed the S&P 500 over this period: $30,565 against $42,376.
A $10,000 investment in GILD in October 2016 would be worth about $30,565 today with dividends reinvested, compared with about $42,376 for the same investment in the S&P 500 benchmark (also with dividends reinvested).
Seasonal patterns
Which calendar months have been kind to GILD, and which have not.
Strongest month, January: an average of +4.90%, up in 6 of 10 years.
Weakest month, May: an average of -1.71%, up in 5 of 10 years.
This month, October: has averaged +2.40%, up in 4 of 9 years. Past seasonality does not repeat on schedule.
Over the last 10 years, GILD's strongest calendar month has been January (average +4.90%, up in 6 of 10 years) and its weakest May (average -1.71%, up in 5 of 10 years).
Average return for each calendar month over the last 10 years, from weekly closing prices with dividends included.
GILD stock price prediction 2030
Thousands of simulated paths from the price history. A range of outcomes, not a forecast.
Monte Carlo projection
Thousands of simulated paths for $10,000 in GILD, from its own past volatility. The shaded area holds 80% of them.
CleaRank's 4-year Monte Carlo simulation, based on 10 years of price history, projects that a $10,000 investment in GILD today could grow to about $13,104 by 2030 in the base case, with a 90th-percentile outcome near $25,276 and a 10th-percentile outcome around $6,794. The simulation models price only; at today's 2.04% yield, dividends would add to these figures. Projections are statistical simulations, not guarantees.
GILD Stock Price Prediction 2030: Simulated Scenarios
The same simulation in share prices, year by year.
CleaRank's simulation projects a price near $208 for GILD by 2030 in the base case, from $159 today (1.3x over 4 years). The 10th-percentile path ends near $108. These are outcomes of a Monte Carlo simulation run on GILD's historical return distribution, not price targets, and they assume no dividends are reinvested.
| Year | 10th percentile | Base case | 90th percentile | range base today |
|---|---|---|---|---|
| 2027 | $123 | $170 | $236 | |
| 2028 | $114 | $182 | $290 | |
| 2029 | $110 | $195 | $344 | |
| 2030 | $108 | $208 | $402 |
Method: a lognormal simulation of GILD's own volatility and capped historical trend, re-run daily; base case is the median path, the outer columns the 10th and 90th percentiles. How the simulation works
GILD insider trading
What the people running the company have bought and sold.
GILD insider trading
Shares the company's directors and officers bought and sold, from their own filings.
Month by month
Open-market purchases above the line, sales below.
Net insider selling: No insider bought GILD shares on the open market in the last 18 months. Sales are often planned in advance or cover tax on vesting shares, so they say less than purchases would.
As of October 27, 2026, GILD insiders reported 55 open-market sales worth $98.6M and no open-market purchases over the last 18 months; grants and option exercises are not counted.
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Sep 22, 2026 | Erin Burkhart
Officer
|
Grant | 2.2K | - |
| Sep 15, 2026 | Andrew D Dickinson
Chief Financial Officer
|
Sell | 3.0K | $435.9K |
| Sep 15, 2026 | Johanna Mercier
Officer
|
Sell | 3.0K | $432.6K |
| Sep 10, 2026 | Dietmar P. Berger
Officer
|
Grant | 533 | - |
| Sep 10, 2026 | Wettan Keeley M Cain
General Counsel
|
Grant | 590 | - |
| Sep 10, 2026 | Andrew D Dickinson
Chief Financial Officer
|
Grant | 2.8K | - |
| Sep 10, 2026 | Johanna Mercier
Officer
|
Grant | 2.8K | - |
| Sep 10, 2026 | Daniel Patrick O'Day
Chief Executive Officer
|
Grant | 8.8K | - |
| Sep 1, 2026 | Daniel Patrick O'Day
Chief Executive Officer
|
Sell | 15.0K | $2.2M |
| Aug 26, 2026 | Anthony Welters
Director
|
Sell | 18.0K | $2.7M |
| Aug 26, 2026 | Anthony Welters
Director
|
Option | 18.0K | $1.1M |
| Aug 20, 2026 | Jeffrey Bluestone
Director
|
Sell | 5.0K | $725.1K |
| Aug 20, 2026 | Jeffrey Bluestone
Director
|
Option | 5.0K | $335.2K |
| Aug 17, 2026 | Johanna Mercier
Officer
|
Sell | 28.0K | $3.9M |
| Aug 17, 2026 | Andrew D Dickinson
Chief Financial Officer
|
Sell | 3.0K | $415.1K |
| Aug 17, 2026 | Johanna Mercier
Officer
|
Option | 25.0K | $1.7M |
| Aug 10, 2026 | Wettan Keeley M Cain
Officer
|
Grant | 6.0K | - |
| Aug 3, 2026 | Daniel Patrick O'Day
Chief Executive Officer
|
Sell | 15.0K | $2.0M |
| Jul 15, 2026 | Andrew D Dickinson
Chief Financial Officer
|
Sell | 3.0K | $389.8K |
| Jul 15, 2026 | Johanna Mercier
Officer
|
Sell | 3.0K | $389.8K |
| Jul 1, 2026 | Daniel Patrick O'Day
Chief Executive Officer
|
Sell | 15.0K | $1.9M |
| Jun 15, 2026 | Andrew D Dickinson
Chief Financial Officer
|
Sell | 3.0K | $376.2K |
| Jun 15, 2026 | Johanna Mercier
Officer
|
Sell | 3.0K | $371.8K |
| Jun 10, 2026 | Dietmar P. Berger
Officer
|
Grant | 533 | - |
| Jun 10, 2026 | Wettan Keeley M Cain
General Counsel
|
Grant | 589 | - |
| Jun 10, 2026 | Andrew D Dickinson
Chief Financial Officer
|
Grant | 2.8K | - |
| Jun 10, 2026 | Johanna Mercier
Officer
|
Grant | 2.8K | - |
| Jun 10, 2026 | Daniel Patrick O'Day
Chief Executive Officer
|
Grant | 8.8K | - |
| Jun 1, 2026 | Daniel Patrick O'Day
Chief Executive Officer
|
Sell | 15.0K | $2.0M |
| May 15, 2026 | Johanna Mercier
Officer
|
Sell | 28.0K | $3.7M |
| May 15, 2026 | Andrew D Dickinson
Chief Financial Officer
|
Sell | 3.0K | $396.8K |
| May 15, 2026 | Johanna Mercier
Officer
|
Option | 25.0K | $1.7M |
| Apr 30, 2026 | Jacqueline K Barton
Director
|
Grant | 1.1K | - |
| Apr 30, 2026 | Jeffrey Bluestone
Director
|
Grant | 1.1K | - |
| Apr 30, 2026 | Sandra Horning
Director
|
Grant | 1.1K | - |
| Apr 30, 2026 | Ted Wendell Love
Director
|
Grant | 1.1K | - |
| Apr 30, 2026 | Harish Manwani
Director
|
Grant | 1.1K | - |
| Apr 30, 2026 | Javier Rodriguez
Director
|
Grant | 1.1K | - |
| Apr 30, 2026 | Anthony Welters
Director
|
Grant | 1.1K | - |
| Apr 28, 2026 | Daniel Patrick O'Day
Chief Executive Officer
|
Sell | 10.0K | $1.3M |
| Apr 15, 2026 | Andrew D Dickinson
Chief Financial Officer
|
Sell | 3.0K | $422.9K |
| Mar 27, 2026 | Daniel Patrick O'Day
Chief Executive Officer
|
Sell | 10.0K | $1.4M |
| Mar 16, 2026 | Andrew D Dickinson
Chief Financial Officer
|
Sell | 3.0K | $432.7K |
| Mar 10, 2026 | Dietmar P. Berger
Officer
|
Grant | 2.1K | - |
| Mar 10, 2026 | Wettan Keeley M Cain
Officer
|
Grant | 1.2K | - |
| Mar 10, 2026 | Andrew D Dickinson
Chief Financial Officer
|
Grant | 6.5K | - |
| Mar 10, 2026 | Johanna Mercier
Officer
|
Grant | 6.6K | - |
| Mar 10, 2026 | Daniel Patrick O'Day
Chief Executive Officer
|
Grant | 20.0K | - |
| Feb 27, 2026 | Daniel Patrick O'Day
Chief Executive Officer
|
Sell | 10.0K | $1.4M |
| Feb 27, 2026 | Dietmar P. Berger
Officer
|
Grant | 8.5K | - |
| Feb 27, 2026 | Wettan Keeley M Cain
General Counsel
|
Grant | 470 | - |
| Feb 27, 2026 | Andrew D Dickinson
Chief Financial Officer
|
Grant | 11.1K | - |
| Feb 27, 2026 | Johanna Mercier
Officer
|
Grant | 11.1K | - |
| Feb 27, 2026 | Daniel Patrick O'Day
Chief Executive Officer
|
Grant | 38.4K | - |
| Feb 17, 2026 | Johanna Mercier
Officer
|
Sell | 28.0K | $4.3M |
| Feb 17, 2026 | Andrew D Dickinson
Chief Financial Officer
|
Sell | 3.0K | $463.3K |
| Feb 17, 2026 | Johanna Mercier
Officer
|
Option | 25.0K | $1.7M |
| Feb 5, 2026 | Daniel Patrick O'Day
Chief Executive Officer
|
Sell | 115.6K | $17.3M |
| Feb 5, 2026 | Daniel Patrick O'Day
Chief Executive Officer
|
Option | 115.6K | $7.6M |
| Feb 3, 2026 | Andrew D Dickinson
Chief Financial Officer
|
Grant | 44.9K | - |
| Feb 3, 2026 | Johanna Mercier
Officer
|
Grant | 44.9K | - |
| Feb 3, 2026 | Daniel Patrick O'Day
Chief Executive Officer
|
Grant | 131.7K | - |
| Jan 28, 2026 | Daniel Patrick O'Day
Chief Executive Officer
|
Sell | 10.0K | $1.4M |
| Jan 23, 2026 | Daniel Patrick O'Day
Chief Executive Officer
|
Sell | 115.6K | $15.6M |
| Jan 23, 2026 | Daniel Patrick O'Day
Chief Executive Officer
|
Option | 115.6K | $7.6M |
| Jan 20, 2026 | Jeffrey Bluestone
Director
|
Sell | 5.0K | $617.5K |
| Jan 20, 2026 | Jeffrey Bluestone
Director
|
Option | 5.0K | $337.3K |
| Jan 15, 2026 | Andrew D Dickinson
Chief Financial Officer
|
Sell | 3.0K | $372.9K |
| Jan 2, 2026 | Dietmar P. Berger
Officer
|
Grant | 16.3K | - |
| Dec 29, 2025 | Daniel Patrick O'Day
Chief Executive Officer
|
Sell | 10.0K | $1.2M |
| Dec 15, 2025 | Andrew D Dickinson
Chief Financial Officer
|
Sell | 3.0K | $366.0K |
| Dec 10, 2025 | Andrew D Dickinson
Chief Financial Officer
|
Grant | 3.7K | - |
| Dec 10, 2025 | Johanna Mercier
Officer
|
Grant | 3.8K | - |
| Dec 10, 2025 | Daniel Patrick O'Day
Chief Executive Officer
|
Grant | 10.4K | - |
| Nov 28, 2025 | Daniel Patrick O'Day
Chief Executive Officer
|
Sell | 10.0K | $1.3M |
| Nov 28, 2025 | Kelly A Kramer
Director
|
Sell | 5.6K | $713.2K |
| Nov 28, 2025 | Jeffrey Bluestone
Director
|
Sell | 5.0K | $625.4K |
| Nov 28, 2025 | Jeffrey Bluestone
Director
|
Option | 5.0K | $324.6K |
| Nov 28, 2025 | Kelly A Kramer
Director
|
Option | 5.6K | $454.5K |
| Nov 17, 2025 | Johanna Mercier
Officer
|
Sell | 28.0K | $3.5M |
| Nov 17, 2025 | Andrew D Dickinson
Chief Financial Officer
|
Sell | 2.5K | $313.1K |
| Nov 17, 2025 | Johanna Mercier
Officer
|
Option | 25.0K | $1.7M |
| Nov 12, 2025 | Deborah H Telman
General Counsel
|
Sell | 53.6K | $6.6M |
| Nov 12, 2025 | Deborah H Telman
General Counsel
|
Option | 53.6K | $3.5M |
| Oct 28, 2025 | Daniel Patrick O'Day
Chief Executive Officer
|
Sell | 10.0K | $1.2M |
| Oct 24, 2025 | Deborah H Telman
General Counsel
|
Grant | 515 | - |
| Oct 15, 2025 | Johanna Mercier
Officer
|
Sell | 3.0K | $354.2K |
| Oct 15, 2025 | Andrew D Dickinson
Chief Financial Officer
|
Sell | 2.5K | $295.2K |
| Sep 29, 2025 | Daniel Patrick O'Day
Chief Executive Officer
|
Sell | 10.0K | $1.1M |
| Sep 15, 2025 | Johanna Mercier
Officer
|
Sell | 3.0K | $340.7K |
| Sep 15, 2025 | Andrew D Dickinson
Chief Financial Officer
|
Sell | 2.5K | $283.9K |
| Sep 10, 2025 | Andrew D Dickinson
Chief Financial Officer
|
Grant | 3.7K | - |
| Sep 10, 2025 | Johanna Mercier
Officer
|
Grant | 3.8K | - |
| Sep 10, 2025 | Daniel Patrick O'Day
Chief Executive Officer
|
Grant | 10.4K | - |
| Sep 10, 2025 | Deborah H Telman
General Counsel
|
Grant | 1.3K | - |
| Sep 10, 2025 | Diane E Wilfong
Officer
|
Grant | 921 | - |
| Aug 28, 2025 | Daniel Patrick O'Day
Chief Executive Officer
|
Sell | 10.0K | $1.1M |
| Aug 15, 2025 | Johanna Mercier
Officer
|
Sell | 28.0K | $3.3M |
| Aug 15, 2025 | Andrew D Dickinson
Chief Financial Officer
|
Sell | 2.5K | $296.3K |
| Aug 15, 2025 | Johanna Mercier
Officer
|
Option | 25.0K | $1.7M |
| Jul 28, 2025 | Daniel Patrick O'Day
Chief Executive Officer
|
Sell | 10.0K | $1.1M |
| Jul 25, 2025 | Deborah H Telman
General Counsel
|
Grant | 8.7K | - |
| Jul 15, 2025 | Johanna Mercier
Officer
|
Sell | 3.0K | $333.1K |
| Jul 15, 2025 | Andrew D Dickinson
Chief Financial Officer
|
Sell | 2.5K | $277.6K |
| Jul 14, 2025 | Jeffrey Bluestone
Director
|
Sell | 5.0K | $548.7K |
| Jul 14, 2025 | Jeffrey Bluestone
Director
|
Option | 5.0K | $337.3K |
| Jun 30, 2025 | Daniel Patrick O'Day
Chief Executive Officer
|
Sell | 10.0K | $1.1M |
| Jun 16, 2025 | Johanna Mercier
Officer
|
Sell | 3.0K | $330.5K |
| Jun 16, 2025 | Andrew D Dickinson
Chief Financial Officer
|
Sell | 2.5K | $275.4K |
| Jun 10, 2025 | Andrew D Dickinson
Chief Financial Officer
|
Grant | 3.7K | - |
| Jun 10, 2025 | Johanna Mercier
Officer
|
Grant | 3.8K | - |
| Jun 10, 2025 | Daniel Patrick O'Day
Chief Executive Officer
|
Grant | 10.4K | - |
| Jun 10, 2025 | Deborah H Telman
General Counsel
|
Grant | 1.3K | - |
| Jun 10, 2025 | Diane E Wilfong
Officer
|
Grant | 920 | - |
| May 30, 2025 | Daniel Patrick O'Day
Chief Executive Officer
|
Sell | 10.0K | $1.1M |
| May 22, 2025 | Johanna Mercier
Officer
|
Sell | 28.0K | $3.0M |
| May 22, 2025 | Johanna Mercier
Officer
|
Option | 25.0K | $1.7M |
| May 15, 2025 | Andrew D Dickinson
Chief Financial Officer
|
Sell | 2.5K | $249.6K |
| May 7, 2025 | Jacqueline K Barton
Director
|
Grant | 1.5K | - |
| May 7, 2025 | Sandra Horning
Director
|
Grant | 1.5K | - |
Source: TwelveData, from SEC Form 4 filings
GILD stock forecast: questions people ask
Answered from the figures on this page, as of October 27, 2026.